SynAct Pharma AB (OSTO:SYNACT) ROE % Adjusted to Book Value: -10.61% (As of Mar. 2026)


OSTO:SYNACT SynAct Pharma AB OSTO:SYNACT
22 GF Score
Price kr21.05
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB ROE % Adjusted to Book Value?

SynAct Pharma AB OSTO:SYNACT +14.40% 22 ROE % Adjusted to Book Value is -10.61% as of Mar. 2026. GuruFocus rates OSTO:SYNACT with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

SynAct Pharma AB's ROE % for the quarter that ended in Mar. 2026 was -56.01%. SynAct Pharma AB's PB Ratio for the quarter that ended in Mar. 2026 was 5.28. SynAct Pharma AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -10.61%.

SynAct Pharma AB ROE % Adjusted to Book Value Related Terms

SynAct Pharma AB ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for SynAct Pharma AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynAct Pharma AB ROE % Adjusted to Book Value Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.13 -7.05 -80.11 -21.65 -8.14

SynAct Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.70 -11.98 -11.92 -7.10 -10.61

OSTO:SYNACT vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, SynAct Pharma AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SynAct Pharma AB ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's ROE % Adjusted to Book Value falls into.


OSTO:SYNACT
22GF Score
SynAct Pharma AB OSTO:SYNACT
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB ROE % Adjusted to Book Value Calculation

SynAct Pharma AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-57.65% / 7.08
=-8.14%

SynAct Pharma AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-56.01% / 5.28
=-10.61%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -10.61% mean?
SynAct Pharma AB (OSTO:SYNACT) has a ROE % Adjusted to Book Value of -10.61% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on SynAct Pharma AB and its competitors.
Is SynAct Pharma AB's ROE % Adjusted to Book Value too high?
SynAct Pharma AB's current ROE % Adjusted to Book Value is -10.61%. Overall, SynAct Pharma AB has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's ROE % Adjusted to Book Value compare to VRTX and REGN?
SynAct Pharma AB's ROE % Adjusted to Book Value of -10.61% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on SynAct Pharma AB and its competitors. SynAct Pharma AB's current ROE % Adjusted to Book Value is -10.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (OSTO:SYNACT) has a current ROE % Adjusted to Book Value of -10.61%. The current ROE % Adjusted to Book Value is -10.61%. SynAct Pharma AB's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For SynAct Pharma AB (OSTO:SYNACT), the current ROE % Adjusted to Book Value is -10.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SynAct Pharma AB Business Description

Other Exchanges 8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
22GF Score

Get the complete analysis for OSTO:SYNACT

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr21.05
Price